Circulating IL-23 Levels and Correlation with SLE Disease Activity: A Meta-Analysis

Abstract

Objective

This study aimed to evaluate the relationship between circulating interleukin-23 (IL-23) levels and systemic lupus erythematosus (SLE) as well as the correlation between plasma/serum IL-23 levels and SLE activity.

Methods

The MEDLINE, EMBASE, and Web of Science databases were searched for relevant publications up to February 2025. We performed a meta-analysis comparing plasma/serum IL-23 levels between patients with SLE and healthy controls and examined correlation coefficients between circulating IL-23 levels and SLE disease activity.

Results

Sixteen studies comprising 1,125 patients with systemic lupus erythematosus (SLE) and 774 healthy controls were included. Circulating IL-23 levels were significantly elevated in the SLE group compared with controls (standardised mean difference [SMD]=1.225, 95% confidence interval [CI]=10.803–1.647, p<0.001). Subgroup analyses confirmed consistent findings across ethnic groups (European, Asian, and Arab populations), and the results remained significant irrespective of study size, with both large-sample (n>70) and small-sample (n<70) studies demonstrating higher IL-23 levels in SLE. Stratification by publication year showed that this association persisted in both recent (after 2017) and older (before 2017) publications, indicating temporal stability of the findings. Disease activity analysis revealed significantly higher IL-23 levels in patients with active disease (SLEDAI≥6) compared with those with inactive SLE (SLEDAI<6) (SMD=0.928, 95% CI=0.351–1.505, p<0.001). A pooled analysis of correlation coefficients indicated a trend toward a positive association between circulating IL-23 levels and SLEDAI scores, although this did not reach statistical significance. However, a significant positive correlation was identified between IL-23 levels and anti-dsDNA (correlation coefficient=0.388, 95% CI=0.189–0.556, p<0.001).

Conclusions

Elevated circulating IL-23 levels were significantly associated with SLE and with disease activity. These findings enhance our understanding of SLE pathogenesis and suggest that IL-23 could serve as a biomarker for monitoring disease activity in SLE.

Keywords

systemic lupus erythematosus - interleukin-23 - disease activity - inflammatory markers - meta-analysis

Schlüsselwörter

Systemischer Lupus erythematodes - Interleukin-23 - Krankheitsaktivität - Entzündungsmarker - Metaanalyse

Publication History

Received: 28 June 2025

Accepted: 06 October 2025

Article published online:
04 December 2025

• References

• 1 Han J-Y, Cho S-K, Sung Y-K. Epidemiology of systemic lupus erythematosus in Korea. J Rheum Dis 2023; 30: 211-219
• 2 Al-Mayouf SM, Hamad A, Kaidali W. et al. Clinical characteristics and prognostic value of autoantibody profile in children with monogenic lupus. J Rheum Dis 2024; 31: 143-150
• 3 Xiong D-K, Shi X, Han M-M. et al. The regulatory mechanism and potential application of IL-23 in autoimmune diseases. Frontiers in Pharmacology 2022; 13: 982238
• 4 Boniface K, Blom B, Liu YJ. et al. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunological reviews 2008; 226: 132-146
• 5 Paquissi FC, Abensur H. The Th17/IL-17 axis and kidney diseases, with focus on lupus nephritis. Frontiers in medicine 2021; 8: 654912
• 6 Haroon MM, Hegazy GA, Hassanien MA. et al. Significance of interleukin 23 in systemic lupus patients: relation to disease activity and damage indices. Biologics: Targets and Therapy. 2023: 1-9
• 7 Carlsson E, Midgley A, Perkins S. et al. Serum protein signatures differentiate paediatric autoimmune/inflammatory disorders. Clinical Immunology 2021; 229: 108790
• 8 Li M, Yang C, Wang Y. et al. The expression of P2X7 receptor on Th1, Th17, and regulatory T cells in patients with systemic lupus erythematosus or rheumatoid arthritis and its correlations with active disease. The Journal of Immunology 2020; 205: 1752-1762
• 9 Dedong H, Feiyan Z, Jie S. et al. Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients. Immunology Letters 2019; 210: 33-39
• 10 Idborg H, Eketjäll S, Pettersson S. et al. TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. Lupus Science & Medicine 2018; 5: e000260
• 11 Fischer K, Przepiera-Będzak H, Sawicki M. et al. Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease. Mediators of Inflammation 2017; 2017: 9401432
• 12 Shahin D, El-Farahaty R, Houssen M. et al. Serum 25-OH vitamin D level in treatment-naïve systemic lupus erythematosus patients: Relation to disease activity, IL-23 and IL-17. Lupus 2017; 26: 917-926
• 13 Zickert A, Amoudruz P, Sundström Y. et al. IL-17 and IL-23 in lupus nephritis-association to histopathology and response to treatment. BMC immunology 2015; 16: 1-10
• 14 Talaat RM, Mohamed SF, Bassyouni IH. et al. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine 2015; 72: 146-153
• 15 Qiu F, Song L, Yang N. et al. Glucocorticoid downregulates expression of IL-12 family cytokines in systemic lupus erythematosus patients. Lupus 2013; 22: 1011-1016
• 16 Mak A, Tang C. Ho RC-m. Serum tumour necrosis factor-alpha is associated with poor health-related quality of life and depressive symptoms in patients with systemic lupus erythematosus. Lupus 2013; 22: 254-261
• 17 Rana A, Minz R, Aggarwal R. et al. Gene expression of cytokines (TNF-α, IFN-γ), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus 2012; 21: 1105-1112
• 18 Abou Ghanima AT, Elolemy GG, Ganeb SS. et al. Role of T helper 17 cells in the pathogenesis of systemic lupus erythematosus. Egypt J Immunol 2012; 19: 25-33
• 19 Cheng F, Guo Z, Xu H. et al. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Annals of the rheumatic diseases 2009; 68: 604-606
• 20 Wong CK, Lit LCW, Tam LS. et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clinical immunology 2008; 127: 385-393
• 21 Robak E, Kulczycka-Siennicka L, Gerlicz Z. et al. Correlations between concentrations of interleukin (IL)-17A, IL-17B and IL-17F, and endothelial cells and proangiogenic cytokines in systemic lupus erythematosus patients. European Cytokine Network 2013; 24: 60-68
• 22 Tang Y-Y, Wang D-C, Chen Y-Y. et al. Th1-related transcription factors and cytokines in systemic lupus erythematosus. Frontiers in Immunology 2023; 14: 1305590
• 23 Lee YH, Song GG. Circulating leptin and its correlation with rheumatoid arthritis activity: a meta-analysis. J Rheum Dis 2023; 30: 116-125
• 24 Lee YH, Song GG. Associations between circulating interleukin-18 levels and adult-onset Still’s disease: a meta-analysis. J Rheum Dis 2025; 32: 48-56
• 25 Lee YH, Song GG. Diagnostic accuracy of dual-energy computed tomography in patients with gout: a meta-analysis. In: Seminars in arthritis and rheumatism. Elsevier; 2017: 95-101
• 26 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 2009; 6: e1000097
• 27 Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC medical research methodology 2005; 5: 13
• 28 Lee YH. An overview of meta-analysis for clinicians. The Korean journal of internal medicine 2017; 33: 277
• 29 Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edn. Hillsdale, New Jersey: L. In: Erlbaum; 1988
• 30 Lee YH, Song GG. Circulating VEGF levels and genetic polymorphisms in Beh&ccedil;et&rsquo;s disease: a meta-analysis. J Rheum Dis 2025; 32: 122-129
• 31 Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. Bmj 1997; 315: 1533-1537
• 32 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
• 33 Shahdadian M, Saghiri MA, Capitle E. Efficacy of early rituximab treatment in primary Sj&#246;gren’s syndrome: a systematic review and meta-analysis. J Rheum Dis 2025; 32: 211-224
• 34 Lee YH. Meta-analysis of genetic association studies. Annals of laboratory medicine 2015; 35: 283
• 35 Waitayangkoon P, Leesutipornchai T, Techasatian W. et al. Urate-lowering therapy is associated with a reduced risk of arrhythmias: a systematic review and meta-analysis. J Rheum Dis 2024; 31: 108-115
• 36 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558
• 37 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
• 38 Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463
• 39 Schinocca C, Rizzo C, Fasano S. et al. Role of the IL-23/IL-17 pathway in rheumatic diseases: an overview. Frontiers in immunology 2021; 12: 637829
• 40 Bianchi E, Rogge L. The IL-23/IL-17 pathway in human chronic inflammatory diseases–new insight from genetics and targeted therapies. Microbes and Infection 2019; 21: 246-253
• 41 Izati AF, Mohd Shukri ND, Wan Ghazali WS. et al. Increased IL-23R+ Th cells population exhibits higher SLEDAI-2K scores in systemic lupus erythematosus patients. Frontiers in immunology 2021; 12: 690908
• 42 van Vollenhoven RF, Kalunian KC, Dörner T. et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases 2022; 81: 1556-1563
• 43 Morand EF, Vital EM, Petri M. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). The Lancet 2023; 401: 1001-1010